Human milk contains more than nutrients; it carries a quiet, evolutionary intelligence expressed through chemistry. It is not conscious thought, but the slow wisdom of evolution written into molecules that nourish, protect, and guide.
Among its most remarkable ingredients are the human milk oligosaccharides (HMOs). These complex sugars, present at around 0.5 to 1.5 g/dL, are not there to feed the infant directly.
They move through the stomach and small intestine largely untouched, reaching the large intestine where they encounter their intended partners, microbes, most notably Bifidobacterium longum subsp. infantis. In return for this nourishment, these microbes produce metabolites such as acetate and lactate that help the infant’s gut mature, influence immune responses, and discourage harmful organisms. HMOs also behave as molecular decoys, occupying binding sites that pathogens might otherwise exploit.
Milk, microbes, and the infant gut are thus engaged in a three-way biological conversation whose outcome is health.
A tribute to motherhood
What makes this even more striking is that HMOs are largely a human gift. Other mammals, such as cows and goats, produce far smaller amounts, often hundreds to thousands-fold less. Human milk is unusually rich in these sugars, as if evolution placed special emphasis on nourishing not only the infant but also the protective microbes that will help defend the infant’s earliest life. In that sense, this chemistry is not merely biology; it is a quiet tribute to human motherhood.
It is worth noticing how unusual this system is. The mother produces sugars her infant cannot digest, and microbes complete the circuit by turning those sugars into nourishment and protection. Care emerges through cooperation.
The logic of lactose
Yet the quiet intelligence of human milk is not expressed only through HMOs. It is also present in the very choice of its main sugar: lactose. Human milk contains lactose, and not simply glucose or maltose. Why this is so invites its own lesson in quiet metabolic design.
Lactose provides 40 to 45 percent of the total energy. Fat provides about the same, but fat does not pass through the glycolytic pathway. Beta-oxidation occurs only in mitochondria. That distinction is consequential.
In this sense, HMOs and lactose are like married partners at a distance, two sugars with very different destinies, yet bound to the same purpose. One works through the microbiome, shaping the infant’s earliest ecology of protection. The other works through metabolism, supplying energy while releasing glucose and galactose that may help fine-tune energy regulation in the newborn.
Galactose and metabolic discipline
Galactose, in particular, carries intriguing implications. In isolated cell cultures, galactose has been shown to force a metabolic shift away from glycolysis, making cells more dependent on mitochondrial oxidative phosphorylation for energy. Cells with defective mitochondria are likely eliminated because they fail to meet energy demand. Thus, the presence of galactose may allow selection for better metabolic adaptation.
One might imagine that this metabolic discipline matters especially in early life, when so much of the infant’s energy, including the substantial fraction coming from fat, must ultimately be processed through mitochondria. Mitochondria themselves are inherited from the mother, and their populations within cells may not be uniform. Survival, growth, and energetic stability may depend on favoring the best-performing metabolic machinery.
In that light, lactose is not merely fuel. It may be part of a quiet sorting mechanism, ensuring that energy metabolism is not only abundant, but resilient.
Intelligence without a thinker
Human milk contains lactose (about 6.5 to 7.5 g per 100 mL), a sugar that the infant gut breaks down with lactase into glucose and galactose for absorption. While this does not imply the same metabolic effects seen in isolated cell culture, it raises the possibility that early-life nutrition may subtly influence metabolic programming, much as has been proposed for HMOs.
The coordination is striking. Lactase is highly active in infancy, precisely when milk is the primary food, but in many humans its expression fades with time. Adults often have much lower levels of the enzyme, and in some, lactase becomes so limited that lactose intolerance emerges. In that sense, lactose is not only a sugar in milk, but part of a timed biological partnership between nourishment and the infant gut, another layer of evolutionary design that works most powerfully at the beginning of life.
Here there is a philosophical lesson. We often assume that intelligence requires a mind, a thinker who designs systems for a purpose. HMOs suggest otherwise. Lactose suggests the same. Human milk appears to “know” how to nourish not only the infant but also the microbial world that sustains the infant, and perhaps even the metabolic pathways through which energy is used.
This is intelligence without a thinker; structure without deliberate intent. Through chemistry, the mother’s body expresses a deeply relational form of care shaped over evolutionary time.
So when the system falters, the problem is not the milk. It is the broken conversation between milk, microbes, and the infant gut. And in the quiet success of that conversation, in sugars that feed bacteria, in sugars that shape metabolism, in energy that must pass through mitochondria, we glimpse how evolution has woven love and biology together.
Dedicated to all mothers who show love, even in evolution.
Rao M. Uppu is professor of environmental toxicology and chemistry at Southern University and A&M College in Baton Rouge, Louisiana, where he has served since 2002. He is also an adjunct professor of chemistry and pathobiological sciences at Louisiana State University.
Trained in biochemistry, physical organic chemistry, and free radical chemistry, his research spans bioanalytical methods, biomarker discovery and validation, chemical toxicology, environmental chemistry, computational genomics, reactive intermediates, and the molecular mechanisms of disease. His scholarship is indexed on ORCID, ResearchGate, and Google Scholar.
Dr. Uppu is a Fellow of the American Association for the Advancement of Science (AAAS), the Royal Society of Chemistry (RSC), the Royal Society of Biology (RSB), the Royal Society of Medicine (RSM), the Royal Society for Public Health (RSPH), and the Academy of Toxicological Sciences (ATS).
In addition to his scientific research, he writes reflective essays on scientific culture, mentorship, peer review, ethics, and the human dimensions of academic life. He shares updates on LinkedIn.
